Daniel Wright

List of Publications by Year
in descending order

62 papers	929 citations	516710 16 h-index	501196 28 g-index
63 all docs	63 docs citations	63 times ranked	1192 citing authors

#	Article	IF	Citations
1	The propagation of betweenâ€subject variability from dose to response. British Journal of Clinical Pharmacology, 2022, 88, 1414-1417.	2.4	2
2	Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review. International Journal of Pharmacy Practice, 2022, 30, 215-225.	0.6	4
3	Perspectives on the past, present, and future of pharmacometrics. British Journal of Clinical Pharmacology, 2022, 88, 1403-1405.	2.4	0
4	Therapeutic decision-making in primary care pharmacy practice. Research in Social and Administrative Pharmacy, 2021, 17, 326-331.	3.0	4
5	A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVIDâ€19 (SARSâ€COVâ€2) treatments. British Journal of Clinical Pharmacology, 2021, 87, 707-711.	2.4	20
6	Understanding the association between metformin plasma concentrations and lactate. British Journal of Clinical Pharmacology, 2021, 87, 700-701.	2.4	5
7	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. Annual Review of Pharmacology and Toxicology, 2021, 61, 225-245.	9.4	74
8	Evaluation of designs for renal drug studies based on the European Medicines Agency and Food and Drug Administration guidelines for drugs that are predominantly secreted. British Journal of Clinical Pharmacology, 2021, 87, 1401-1410.	2.4	2
9	Metformin doses to ensure efficacy and safety in patients with reduced kidney function. PLoS ONE, 2021, 16, e0246247.	2.5	8
10	Nonmedical use of prescription drugs. British Journal of Clinical Pharmacology, 2021, 87, 1635-1636.	2.4	4
11	Does the intact nephron hypothesis provide a reasonable model for metformin dosing in chronic kidney disease?. British Journal of Clinical Pharmacology, 2021, , .	2.4	1
12	Science fiction has become reality: Best practice for future viral pandemics. British Journal of Clinical Pharmacology, 2021, 87, 3385-3387.	2.4	0
13	Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urateâ€Lowering Responseâ€”In Search of a Minimum Effective Oxypurinol Concentration. Clinical and Translational Science, 2020, 13, 110-115.	3.1	6
14	The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF). European Journal of Clinical Pharmacology, 2020, 76, 239-247.	1.9	5
15	Kineticâ€pharmacodynamic model for drugs with nonâ€linear elimination: Parameterisation matters. British Journal of Clinical Pharmacology, 2020, 86, 196-198.	2.4	4
16	Measuring the Development of Therapeutic-Decision-Making Skills by Practicing Pharmacists Undertaking a University-Based Postgraduate Clinical Qualification at Distance. Pharmacy (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	k
17	The pharmacokinetics of metformin in patients receiving intermittent haemodialysis. British Journal of Clinical Pharmacology, 2020, 86, 1430-1443.	2.4	4
18	How do pharmacy students describe decision-making about drug therapy?. MedEdPublish, 2020, 9, .	0.3	1

#	Article	IF	Citations
19	Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamics in Clinical Pharmacology. , 2020, , 903-927.		0
20	Clinical decision-making: An essential skill for 21st century pharmacy practice. Research in Social and Administrative Pharmacy, 2019, 15, 600-606.	3.0	30
21	Understanding the process of clinical judgement for pharmacists when making clinical decisions. Research in Social and Administrative Pharmacy, 2019, 15, 607-614.	3.0	4
22	Evaluation of Assumptions Underpinning Pharmacometric Models. AAPS Journal, 2019, 21, 97.	4.4	3
23	Spotlight Commentary: Modelâ€informed precision dosing must demonstrate improved patient outcomes. British Journal of Clinical Pharmacology, 2019, 85, 2238-2240.	2.4	17
24	TheÂAssociation between Metformin Therapy and Lactic Acidosis. Drug Safety, 2019, 42, 1449-1469.	3.2	22
25	Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate!. British Journal of Clinical Pharmacology, 2019, 85, 1378-1379.	2.4	5
26	The intact nephron hypothesis as a model for renal drug handling. European Journal of Clinical Pharmacology, 2019, 75, 147-156.	1.9	17
27	The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool. British Journal of Clinical Pharmacology, 2018, 84, 937-943.	2.4	11
28	â€˜Massiveâ€™ metformin overdose. British Journal of Clinical Pharmacology, 2018, 84, 2923-2927.	2.4	20
29	A philosophical framework for pharmacy in the 21st century guided by ethical principles. Research in Social and Administrative Pharmacy, 2018, 14, 309-316.	3.0	21
30	Response to â€˜Comment on â€˜Massiveâ€™ metformin overdoseâ€™ by Chiew et al.â€™. British Journal of Clinical Pharmacology, 2018, 84, 2940-2941.	2.4	3
31	Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamics in Clinical Pharmacology. , 2018, , 1-26.		1
32	A factor VII-based method for the prediction of anticoagulant response to warfarin. Scientific Reports, 2018, 8, 12041.	3.3	4
33	Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring â‰¥7 mg Daily: A Systematic Review and Metaâ€analysis. Clinical Pharmacology and Therapeutics, 2017, 102, 297-304.	4.7	16
34	A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins. Clinical Pharmacokinetics, 2017, 56, 1555-1566.	3.5	9
35	Individualising the dose of allopurinol in patients with gout. British Journal of Clinical Pharmacology, 2017, 83, 2015-2026.	2.4	17
36	A general empirical model for renal drug handling in pharmacokinetic analyses. British Journal of Clinical Pharmacology, 2017, 83, 1869-1872.	2.4	7

#	Article	IF	Citations
37	Deterministic identifiability of population pharmacokinetic and pharmacokineticâ€“pharmacodynamic models. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 415-423.	1.8	9
38	A Population Pharmacokinetic Model for 51Cr EDTA to Estimate Renal Function. Clinical Pharmacokinetics, 2017, 56, 671-678.	3.5	2
39	A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis. European Journal of Clinical Pharmacology, 2017, 73, 71-78.	1.9	14
40	Predicting allopurinol response in patients with gout. British Journal of Clinical Pharmacology, 2016, 81, 277-289.	2.4	46
41	Influence of Genotype on Warfarin Maintenance Dose Predictions Produced Using a Bayesian Dose Individualization Tool. Therapeutic Drug Monitoring, 2016, 38, 677-683.	2.0	10
42	Methods for Predicting Warfarin Dose Requirements. Therapeutic Drug Monitoring, 2015, 37, 531-538.	2.0	16
43	What do we learn from repeated population analyses?. British Journal of Clinical Pharmacology, 2015, 79, 40-47.	2.4	21
44	Letter by Chin et al Regarding Article, â€œEfficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 457 T	2.6	1
45	A proposal for doseâ€adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time. British Journal of Clinical Pharmacology, 2014, 78, 599-609.	2.4	25
46	Dabigatran in Patients with Mechanical Heart Valves. New England Journal of Medicine, 2014, 370, 381-384.	27.0	13
47	Impaired response or insufficient dosage?â€”Examining the potential causes of â€œinadequate responseâ€• to allopurinol in the treatment of gout. Seminars in Arthritis and Rheumatism, 2014, 44, 170-174.	3.4	43
48	Frequency of CYP2C9 polymorphisms in polynesian people and potential relevance to management of gout with benzbromarone. Joint Bone Spine, 2014, 81, 160-163.	1.6	8
49	Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C. Drugs in R and D, 2014, 14, 113-123.	2.2	38
50	Learning More From the Dabigatran Concentrations in the RE-LY Study. Journal of the American College of Cardiology, 2014, 63, 2746-2747.	2.8	3
51	Coagulation assays and plasma fibrinogen concentrations in realâ€world patients with atrial fibrillation treated with dabigatran. British Journal of Clinical Pharmacology, 2014, 78, 630-638.	2.4	16
52	The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. European Journal of Clinical Pharmacology, 2013, 69, 1411-1421.	1.9	26
53	A Bayesian Dose-Individualization Method for Warfarin. Clinical Pharmacokinetics, 2013, 52, 59-68.	3.5	41
54	Is the dose of dabigatran really more predictable than warfarin?. British Journal of Clinical Pharmacology, 2013, 76, 997-998.	2.4	4

#	Article	IF	Citations
55	Challenges in integrating a complex systems computer simulation in class: An educational design research. Australasian Journal of Educational Technology, 2012, 28, .	3.5	3
56	Dabigatran: rational dose individualisation and monitoring guidance is needed. New Zealand Medical Journal, 2012, 125, 148-54.	0.5	9
57	Interpreting population pharmacokineticâ€pharmacodynamic analyses â€“ a clinical viewpoint. British Journal of Clinical Pharmacology, 2011, 71, 807-814.	2.4	86
58	Understanding the time course of pharmacological effect: a PKPD approach. British Journal of Clinical Pharmacology, 2011, 71, 815-823.	2.4	74
59	The Influence of Dosing Time, Variable Compliance and Circadian Low-Density Lipoprotein Production on the Effect of Simvastatin: Simulations from a Pharmacokinetic-Pharmacodynamic Model. Basic and Clinical Pharmacology and Toxicology, 2011, 109, 494-498.	2.5	10
60	Development of a Bayesian Forecasting Method for Warfarin Dose Individualisation. Pharmaceutical Research, 2011, 28, 1100-1111.	3.5	27
61	The â€˜apparent clearanceâ€™ of free phenytoin in elderly vs. younger adults. British Journal of Clinical Pharmacology, 2010, 70, 132-138.	2.4	14
62	Falsely elevated vancomycin plasma concentrations sampled from central venous implantable catheters (portacaths). British Journal of Clinical Pharmacology, 2010, 70, 769-772.	2.4	13